Induction outcome and differentiation syndrome of APL patients in the PETHEMA LPA99 and LPA2005 trials
| Characteristic . | LPA99 . | LPA2005 . | P . | ||
|---|---|---|---|---|---|
| Median (range) . | N (%) . | Median (range) . | N (%) . | ||
| Overall | 561 (100) | 402 (100) | |||
| Morphologic CR | 511 (91.1) | 372 (92.5) | .42 | ||
| Days to CR | 37 (21-77) | 39 (18-81) | .38 | ||
| Days to PMN > 1 × 109/L | 23 (0-60) | 24 (6-72) | .36 | ||
| Days to platelets > 50 × 109/L | 19 (0-50) | 19 (4-80) | .08 | ||
| Cause of induction death | |||||
| Hemorrhage | 28 (5.0) | 15 (3.7) | .44 | ||
| Infection | 12 (2.1) | 6 (1.5) | .62 | ||
| Differentiation syndrome | 8 (1.4) | 4 (1.0) | .55 | ||
| Other | 2 (0.4) | 5 (1.2) | .22 | ||
| Differentiation syndrome | |||||
| Severe | 66 (12) | 45 (12) | .12 | ||
| Moderate | 66 (12) | 61 (16) | |||
| Absent | 429 (76) | 266 (72) | |||
| Characteristic . | LPA99 . | LPA2005 . | P . | ||
|---|---|---|---|---|---|
| Median (range) . | N (%) . | Median (range) . | N (%) . | ||
| Overall | 561 (100) | 402 (100) | |||
| Morphologic CR | 511 (91.1) | 372 (92.5) | .42 | ||
| Days to CR | 37 (21-77) | 39 (18-81) | .38 | ||
| Days to PMN > 1 × 109/L | 23 (0-60) | 24 (6-72) | .36 | ||
| Days to platelets > 50 × 109/L | 19 (0-50) | 19 (4-80) | .08 | ||
| Cause of induction death | |||||
| Hemorrhage | 28 (5.0) | 15 (3.7) | .44 | ||
| Infection | 12 (2.1) | 6 (1.5) | .62 | ||
| Differentiation syndrome | 8 (1.4) | 4 (1.0) | .55 | ||
| Other | 2 (0.4) | 5 (1.2) | .22 | ||
| Differentiation syndrome | |||||
| Severe | 66 (12) | 45 (12) | .12 | ||
| Moderate | 66 (12) | 61 (16) | |||
| Absent | 429 (76) | 266 (72) | |||
CR indicates complete response; and PMN, polymorphonuclear leukocytes.